AbbVie Inc. may so far have been playing on the fringes of the Indian market, but its planned $63bn acquisition of Allergan PLC will give it a market-leading presence in the ophthalmology segment in the country and offers significant potential to expand the Botox business, among other growth avenues.
Unusually, AbbVie does not sell its crown jewel Humira (adalimumab) at all in India and only has a small basket of products on the market. By contrast, Allergan, with a larger portfolio, is ranked 55th on the country's fragmented market with sales of around INR5bn ($72
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?